The first clinical trials of a new type of cancer treatment that releases the “brakes” on immune cells indicate that this approach enhances attacks on tumors while sparing the body’s own tissue.
The results of the phase I clinical trials of cytotoxic T-lymphocyte-associated antigen 4 blockade therapy were published online on April 1, 2003, in the Early Edition of the Proceedings of the National Academy of Sciences. The researchers involved in the study included James Allison, a Howard Hughes Medical Institute investigator at the University of California, Berkeley, Glenn Dranoff, Steven Hodi and colleagues from the Dana-Farber Cancer Institute (DFCI), Brigham and Women’s Hospital, Massachusetts General Hospital and Harvard Medical School.
Over the last decade, basic research in Allison’s laboratory and others has shown that the immune-regulating molecule, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), inhibits activated immune system T cells, and prevents them from attacking the body’s own tissues. In studies in mice, Allison and his colleagues identified an antibody that blocks CTLA-4 and showed that it enhances the cancer-fighting activity of certain anti-cancer vaccines. Their research showed that blocking CTLA-4 maintains the response of T cells triggered by the vaccines to attack the cancer.
Jim Keeley | Howard Hughes Medical Institute
Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University
Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
16.11.2018 | Health and Medicine
16.11.2018 | Life Sciences
16.11.2018 | Life Sciences